登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688366 证券简称：昊海生科 公告编号：2025-036 上海昊海生物科技股份有限公司 关于第二期以集中竞价交易方式回购公司 A股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）于2024年8月16日召开第五届董事会第二十五次会 议审议通过了《关于第二期以集中竞价交易方式回购公司A股股份方案的议案》，同意公司以集中竞价 交易方式回购公司A股股份，回购的A股股份拟用于员工持股计划或股权激励，回购资金总额不低于 10,000.00万元（含），不超过20,000.00万元（含），回购价格不超过89.71元/股，回购期限自董事会审 议通过回购股份方案之日起12个月内。具体内容详见公司于2024年8月17日在上海证券交易所网站 （www.sse.com.cn）披露的《上海昊海生物科技股份有限公司关于第二期以集中竞价交易方式回购公司 A股股份的方案暨回购报告书》（公 ...

Core Viewpoint - Haohai Biological Technology announced on the evening of August 1 that it will not implement the A-share share buyback in July 2025 [1] Group 1 - The company released an announcement regarding its decision on share buyback [1]

Core Viewpoint - Haohai Biological Technology (06826) announced that as of July 31, 2025, the company has not implemented an A-share buyback program, having repurchased a total of 1.8324 million A-shares, representing 0.79% of the total share capital of 233 million shares [1] Summary by Category - **Share Buyback Details** - The company repurchased 1.8324 million A-shares through centralized bidding [1] - This represents 0.79% of the total share capital of 233 million shares [1] - The highest transaction price was 63.58 yuan per share, while the lowest was 49.25 yuan per share [1] - The total amount spent on the buyback was 104 million yuan, excluding transaction fees [1]

Core Viewpoint - The company, Haohai Biological Technology (06826), announced that it has not implemented an A-share buyback as of July 2025, with a total of 1.8324 million A-shares repurchased, representing 0.79% of the total share capital of 233 million shares [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased a total of 1.8324 million A-shares through centralized bidding, with a maximum transaction price of 63.58 CNY per share and a minimum transaction price of 49.25 CNY per share [1] - The total amount spent on the buyback was 104 million CNY, excluding transaction fees such as stamp duty and commission [1]

（股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 关于第二期以集中竞价交易方式回购公司 A 股股份的进展公告 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期以集中競價交易方式回購公司A股股份的進展公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月1日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公 司之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-036 上海昊海生物科技股份有限公司（以下简称"公司"）于 2024 年 8 月 16 日召 开第五届董事会第二十五次会议审议通过了《关于第二期以集中竞价交易方式回 购公司 A 股股份方案的议案》，同意公司以集中竞价交易方式回购公司 A 股股份， 回购的 A 股股份拟用于员工持股计划或股权激励，回购资金总额不低于 10,000.00 万元（含），不超过 20,000.00 万元（含），回购价格不超过 89.71 元/股，回购期限 自董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 8 月 17 日在上海证券交易所网站（www.sse.com.cn）披露的《上海昊海生物科技股 份有限公司关于第二期以集中竞价交易方式回购公司 A 股股份的方案暨回购报告 书》（公告编号：2024-042）。 公司 A 股 2024 年半年度权益分派实施完毕后，本次以集中竞价交易方式回购 公司 A 股股份价格上限由不超过 89.71 元/股（含），调整为不超过 89.31 元/股（含）。 具体内容详见公司于 2024 年 10 月 11 ...

格隆汇8月1日丨昊海生科(688366.SH)公布，2025年7月，公司未实施A股股份回购。截至2025年7月31 日，公司通过集中竞价交易方式累计回购公司A股股份1,832,421股，占公司总股本232,581,095股的比例 为0.79%，最高成交价为63.58元/股，最低成交价为49.25元/股，成交总金额为103,905,394.55元（不含印 花税、交易佣金等交易费用）。 ...

Core Insights - The rise of the "silver economy" indicates that the high-net-worth elderly population is expected to become a significant growth engine for the market [1][5]. Group 1: Market Dynamics - Goldman Sachs reports that the medical expenditures of individuals aged 50 and above with net assets exceeding 3 million yuan will be a key driver for the growth of the high-end medical market in China [2]. - This demographic, while only representing 3% of the population over 50, currently contributes 5% of total medical expenditures, which is projected to increase to 13% by 2035 as their population share grows to 5% [3][8]. - The medical spending of this group is expected to rise from 221 billion yuan in 2024 to 963 billion yuan by 2035, reflecting a compound annual growth rate (CAGR) of 14.3%, significantly higher than the overall elderly population growth rate of 5.3% and the all-age growth rate of 4.7% [3][7]. Group 2: Self-Payment Market - As national health insurance budgets tighten, the role of out-of-pocket (OOP) medical expenses is becoming increasingly important, with the self-payment ratio expected to rise from 65% in 2024 to 86% by 2035 [4][9]. - This shift indicates that traditional models reliant on insurance reimbursements are inadequate for meeting the needs of this affluent elderly demographic, which prefers high-quality, elective medical services [9]. Group 3: Health Trends and Opportunities - The report highlights a rising incidence of diseases such as tooth loss, cataracts, and diabetes among the over-50 population, suggesting a growing demand for early screening, preventive care, and high-quality treatment options [10]. - Companies that offer high-end and self-paid medical products are expected to benefit significantly, with revenue growth projected at 13%-21% CAGR, outpacing other business segments [11]. Group 4: Emerging Technologies - The report emphasizes the potential of cutting-edge technologies such as brain-machine interfaces, gene therapies, and rehabilitation robotics to reshape the healthcare industry [4][12]. - The global market for gene medicine is estimated to reach $4.8 trillion, driven by advancements in CRISPR/Cas9 technology and decreasing gene sequencing costs [12]. - Although these technologies are still in early stages, their early applications in healthcare present significant opportunities for growth in the high-end self-pay medical market [13].

Group 1 - The company has completed the repurchase and cancellation of H shares, resulting in a reduction of total share capital from 233,193,695 shares to 232,581,095 shares [1][2] - The repurchase was authorized during the 2023 annual general meeting and subsequent shareholder meetings, allowing the board to proceed with the cancellation of H shares [1] - Following the cancellation, the structure of the share capital has changed, with A shares increasing from 83.2149% to 83.4341% of total shares, while H shares decreased from 16.7851% to 16.5659% [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 证券代码：688366 证券简称：昊海生科 公告编号：2025-035 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於註銷已回購H股股份的公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年7月28日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公 司之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先 ...